Extracellular vesicles Archives - Evercyte

26 09, 2024

Participation to the ASEV and CzeSEV 2024 meeting

Participation to the ASEV and CzeSEV 2024 meeting

By Giulia Corso|2024-09-26T11:26:20+00:00September 26th, 2024|conferences, EV cell factories, EVscale, Extracellular Vesicles, mesenchymal stromal cells|

We participated to the ASEV and CzeSEV 2024 meeting in Vienna, Austria September 26th, 2024, Vienna, Austria We participated to the

27 06, 2024

Evercyte highlights immortalized cell technology at SelectBIO Rotterdam 2024

Evercyte highlights immortalized cell technology at SelectBIO Rotterdam 2024

By Giulia Corso|2024-09-26T11:28:45+00:00June 27th, 2024|cell line development, conferences, EV cell factories, extracellular vesicles, organ-on-a-chip|

Evercyte highlights immortalized cell technology at SelectBIO Rotterdam 2024 June 27th, 2024, Vienna, Austria We participated as technology spotlight speakers at

23 05, 2024

hTERT immortalized ASC for large-scale EV production

hTERT immortalized ASC for large-scale EV production

By Giulia Corso|2024-05-29T13:40:27+00:00May 23rd, 2024|Extracellular vesicles, mesenchymal stromal cells, recent highlights EV, telomerized cells|

Recent publication showcasing our ASC/TERT1 cells as EV production system May 23rd, 2024, Vienna, AustriaOur telomerized human adipose derived MSC (ASC/TERT1, also known in

29 04, 2024

Evercyte proudly introduces the EVscale™ platform

Evercyte proudly introduces the EVscale™ platform

By Giulia Corso|2024-09-26T11:29:18+00:00April 29th, 2024|EVscale, Extracellular vesicles, recent highlights EV|

Evercyte proudly introduces the EVscale™ platform April 29th, 2024, Vienna, Austria The collaborative effort of Evercyte, Phoenestra, and TAmiRNA has yielded the EVscale™ platform,

22 11, 2023

Evercyte Showcases Expertise in Japan’s Pharma Landscape

Evercyte Showcases Expertise in Japan’s Pharma Landscape

By Giulia Corso|2024-09-26T11:30:10+00:00November 22nd, 2023|cell line development, collaboration, EV cell factories, Extracellular Vesicles, mesenchymal stromal cells|

Evercyte Showcases Expertise in Japan’s Pharma Landscape November 22nd, 2023, Vienna, Austria We recently visited Summit Pharmaceuticals International to present our

27 10, 2023

Participation to the first MOVE symposium

Participation to the first MOVE symposium

By Giulia Corso|2024-09-26T11:30:28+00:00October 27th, 2023|Extracellular vesicles and ageing, mesenchymal stromal cells|

We participated to the first MOVE symposium in Malaga, Spain October 27th, 2023, Vienna, Austria We participated to the first MOVE

19 09, 2023

Participation to the Small New World 2.0 meeting

Participation to the Small New World 2.0 meeting

By Giulia Corso|2024-09-26T11:30:55+00:00September 19th, 2023|Extracellular vesicles and ageing, mesenchymal stromal cells|

We participated to the Small New World 2.0 meeting in Graz, Austria September 12th, 2023, Vienna, Austria We participated to the

4 05, 2023

Participation in the CHANGE project

Participation in the CHANGE project

By Giulia Corso|2023-07-11T09:18:04+00:00May 4th, 2023|EU funded project, Extracellular vesicles and ageing, mesenchymal stromal cells|

We are proud to announce our participation in the CHANGE project May 4th, 2023, Vienna, Austria The CHANGE project focuses on

4 04, 2023

Wharton’s jelly MSC-EVs

Wharton’s jelly MSC-EVs

By Giulia Corso|2023-04-05T11:15:37+00:00April 4th, 2023|Extracellular vesicles, mesenchymal stromal cells|

Recent publication showcasing our telomerized Wharton's jelly-MSCs as EV-cell factories April 4th, 2023, Vienna, AustriaOur telomerized Wharton's jelly-derived MSCs (WJ-MSC/TERT273)

17 09, 2021

Recombinant extracellular vesicles

Recombinant extracellular vesicles

By Evercyte|2021-10-08T08:13:44+00:00September 17th, 2021|Extracellular vesicles|

Engineering of CD81 on extracellular vesicles to target specific cell surface proteins. September 17, 2021, Vienna, AustriaWe have developed a platform technology

Title